Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 665

1.

Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.

Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT.

Clin Ther. 2004 Sep;26(9):1400-10.

PMID:
15531002
[PubMed - indexed for MEDLINE]
2.

The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.

Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.

Clin Ther. 2009 Nov;31(11):2665-77. doi: 10.1016/j.clinthera.2009.11.003.

PMID:
20110009
[PubMed - indexed for MEDLINE]
3.

Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.

Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.

Clin Ther. 2011 Dec;33(12):1904-13. doi: 10.1016/j.clinthera.2011.10.025. Epub 2011 Nov 25. Erratum in: Clin Ther. 2012 Feb;34(2):508. Chou, Chih-Chieh [corrected to Chou, Chin-Chieh].

PMID:
22118894
[PubMed - indexed for MEDLINE]
4.

Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin.

Marceille JR, Goins JA, Soni R, Biery JC, Lee TA.

Pharmacotherapy. 2004 Oct;24(10):1317-22.

PMID:
15628829
[PubMed - indexed for MEDLINE]
5.

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study.

Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS.

Diabetes Care. 2003 Nov;26(11):2983-9.

PMID:
14578227
[PubMed - indexed for MEDLINE]
6.
7.

Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication.

Koro CE, Bowlin SJ, Weiss SR.

Pharmacoepidemiol Drug Saf. 2005 Oct;14(10):697-703.

PMID:
15654719
[PubMed - indexed for MEDLINE]
8.

Pioglitazone initiation and subsequent hospitalization for congestive heart failure.

Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM.

Diabet Med. 2005 Aug;22(8):986-93.

PMID:
16026362
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.

Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M; H6E-MC-GLAT study group.

Clin Ther. 2005 May;27(5):554-67.

PMID:
15978304
[PubMed - indexed for MEDLINE]
10.

Considerations for management of fluid dynamic issues associated with thiazolidinediones.

Hollenberg NK.

Am J Med. 2003 Dec 8;115 Suppl 8A:111S-115S. Review.

PMID:
14678876
[PubMed - indexed for MEDLINE]
11.

Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.

Hartung DM, Touchette DR, Bultemeier NC, Haxby DG.

Pharmacotherapy. 2005 Oct;25(10):1329-36.

PMID:
16185176
[PubMed - indexed for MEDLINE]
12.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
[PubMed - indexed for MEDLINE]
13.

Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes.

Toprani A, Fonseca V.

Diabetes Obes Metab. 2011 Mar;13(3):276-80. doi: 10.1111/j.1463-1326.2010.01348.x. Erratum in: Diabetes Obes Metab. 2012 Apr;14(4):386.

PMID:
21205120
[PubMed - indexed for MEDLINE]
14.

Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.

Kalsekar I, Iyer S, Mody R, Rajagopalan R, Kavookjian J.

J Manag Care Pharm. 2006 Mar;12(2):121-9.

PMID:
16515370
[PubMed - indexed for MEDLINE]
Free Article
15.
16.

Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project.

Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, Havranek EP, Krumholz HM.

Diabetes Care. 2005 Jul;28(7):1680-9.

PMID:
15983320
[PubMed - indexed for MEDLINE]
17.

Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.

Balkrishnan R, Arondekar BV, Camacho FT, Shenolikar RA, Horblyuk R, Anderson RT.

Clin Ther. 2007 Jun;29(6 Pt 1):1306-15.

PMID:
18036392
[PubMed - indexed for MEDLINE]
18.

Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.

Panikar V, Chandalia HB, Joshi SR, Fafadia A, Santvana C.

J Assoc Physicians India. 2003 Nov;51:1061-4.

PMID:
15260389
[PubMed - indexed for MEDLINE]
19.

Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting.

Maru S, Koch GG, Stender M, Clark D, Gibowski L, Petri H, White AD, Simpson RJ Jr.

Diabetes Care. 2005 Jan;28(1):20-6.

PMID:
15616228
[PubMed - indexed for MEDLINE]
20.

Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.

Starner CI, Schafer JA, Heaton AH, Gleason PP.

J Manag Care Pharm. 2008 Jul-Aug;14(6):523-31.

PMID:
18693776
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk